PTGS2 and endometriosis: These bioactive compounds reduce the expression of IL-6, IL-8, TNF-α, and COX-2, presenting a reduction of VEGF expression and matrix metalloproteinase-9 activity, thus inhibiting the development of endometriosis [213,214].